Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma. [electronic resource]
Producer: 20170728Description: 58-66 p. digitalISSN:- 1872-7980
- Animals
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis -- drug effects
- Apoptosis Regulatory Proteins -- metabolism
- Bridged Bicyclo Compounds, Heterocyclic -- pharmacology
- Carcinoma, Hepatocellular -- genetics
- Cell Proliferation -- drug effects
- Dose-Response Relationship, Drug
- Gene Expression Regulation, Neoplastic
- Hep G2 Cells
- Humans
- Liver Neoplasms -- genetics
- Male
- Mice, Inbred BALB C
- Mice, Nude
- Myeloid Cell Leukemia Sequence 1 Protein -- metabolism
- Niacinamide -- analogs & derivatives
- Phenylurea Compounds -- pharmacology
- Protein Kinase Inhibitors -- pharmacology
- Pyrimidinones -- pharmacology
- RNA Interference
- RNAi Therapeutics
- Sorafenib
- Transfection
- Wnt Signaling Pathway -- drug effects
- Xenograft Model Antitumor Assays
- beta Catenin -- antagonists & inhibitors
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.